LIMN · Liminatus Pharma, Inc. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“In connection with the Company's assessment of going concern considerations in accordance with Financial Accounting Standards Board ("FASB") ASC 205-40, Presentation of Financial Statements—Going Concern, management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-02 | Valetudo Therapeutics LLC |
10% Owner |
Other↑
Filing footnotes — Common Stock, par value $0.0001 per share (Direct)
Consists of 5,244,351 shares of common stock held of record by Valetudo Therapeutics LLC ("Valetudo"). On July 2, 2026, Valetudo received 3,448,926 shares of common stock and 48,975.10742 shares of the registrant's newly designated Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") as consideration paid to former members of InnocsAI LLC ("InnocsAI") in connection with the registrant's acquisition of InnocsAI. Each share of Series A Preferred Stock will be convertible into 10,000 shares of common stock at an issue price of $0.20 per share, which conversion is contingent upon prior stockholder approval of the issuance of the underlying common shares to the extent required under applicable Nasdaq Stock Market LLC listing rules. The Series A Preferred Stock has no expiration date. Mr. Chris Kim is the CEO and controlling member of Valetudo and has voting and dispositive power over, and may be deemed to be the beneficial owner of, the shares held by Valetudo. The business address of Valetudo is 2251 Stern Goodman Street, Suite E, Fullerton, California 92833. Mr. Kim disclaims any beneficial ownership of any shares held by Valetudo except to the extent of his ultimate pecuniary interest therein. |
Common Stock, par value $0.0001 per share
|
3,448,926 |
| 2026-06-24 | Valetudo Therapeutics LLC |
10% Owner |
Other↓
Filing footnotes — Common Stock, par value $0.0001 per share (Direct)
The reported transaction involves a transfer of securities for which no payment of consideration was received. Consists of 1,795,803 shares of common stock held of record by Valetudo Therapeutics LLC ("Valetudo"). On June 24, 2026, Valetudo transferred 4,373,603 shares of common stock to Ewon Comfortech Co., Ltd and retains voting power over such shares pursuant to a voting agreement. Mr. Chris Kim is the CEO and controlling member of Valetudo and has voting and dispositive power over, and may be deemed to be the beneficial owner of, the shares held by Valetudo. The business address of Valetudo is 2251 Stern Goodman Street, Suite E, Fullerton, California 92833. Mr. Kim disclaims any beneficial ownership of any shares held by Valetudo except to the extent of his ultimate pecuniary interest therein. |
Common Stock, par value $0.0001 per share
|
4,373,603 |